A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

LESSONS LEARNED: Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy‐number gain or gene amplification, a can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Gay, Carl M., Zhou, Yanhong, Lee, J. Jack, Tang, Xi Ming, Lu, Wei, Wistuba, Ignacio I., Ferrarotto, Renata, Gibbons, Don L., Glisson, Bonnie S., Kies, Merrill S., Simon, George R., Heymach, John V., Tsao, Anne S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543335/
https://ncbi.nlm.nih.gov/pubmed/32608142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0610
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados